Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: +14.2% EPS YoY: -43.1% Move: -0.21%

Zomedica Corp

ZOM

$0.0973 -0.21%

Exchange AMEX Sector Healthcare Industry Drug Manufacturers Specialty Generic

Q1 2025

Published: May 9, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ZOM

Reported

Report Date

May 9, 2024

Quarter Q1 2025

Revenue

6.26M

YoY: +14.2%

EPS

-0.01

YoY: -43.1%

Market Move

-0.21%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $6.26M up 14.2% year-over-year
EPS of $-0.01 decreased by 43.1% from previous year
Gross margin of 65.7%
Net income of -9.16M
""The demand for advanced veterinary diagnostics is surging, and we aim to leverage our market position to capture a larger share of this growing sector."" - Zomedica CEO

ZOM

Zomedica Corp

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Apr 2, 2026

Swipe to view all report sections

Executive Summary

Zomedica Corp reported its Q1 2025 results, highlighting a revenue of $6.26 million, reflecting a year-over-year growth of 14.23%, but a quarter-over-quarter decline of 14.65%. The gross profit margin improved to 65.75%, which is a positive indicator amid challenging market conditions. Despite this, the company continues to post a significant net loss of $9.16 million, signaling ongoing operational challenges. Management expressed commitment to refining its product offerings and enhancing market penetration in its earnings call, underscoring a focus on growing diagnostic solutions for companion animals. Investors should monitor upcoming product launches as key drivers of market growth and potential profitability.

Key Performance Indicators

Revenue

Increasing

6.26M

QoQ: -14.65% | YoY: 14.23%

Gross Profit

Increasing

4.12M

65.75% margin

QoQ: 28.54% | YoY: 7.35%

Operating Income

Decreasing

-10.39M

QoQ: 8.81% | YoY: -38.26%

Net Income

Decreasing

-9.16M

QoQ: 59.12% | YoY: -43.46%

EPS

Decreasing

-0.01

QoQ: 59.39% | YoY: -43.08%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue Growth: Zomedica's revenue of $6.26 million for Q1 2025 represents a 14.23% increase year-over-year, showcasing the strong demand for its veterinary diagnostics products. However, the QoQ decrease of 14.65% raises questions about seasonal fluctuations and ongoing operational efficiencies.

Profitability Metrics: The gross profit margin saw an improvement to 65.75%, up from 62.48% in Q4 2024. However, the net income for the quarter was a loss of $9.16 million, reflecting a -43.46% change year-over-year, underscoring persistent cost management issues that must be addressed.

Cash Position: As of the end of Q1 2025, Zomedica had $10.94 million in cash and cash equivalents, down from $12.95 million at the beginning of the quarter. The total assets stood at $243.7 million, supported by a solid current ratio of 11.50.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	6.26M	14.23%	-14.65%
Gross Profit	4.12M	7.35%	28.54%
Operating Income	-10.39M	-38.26%	8.81%
Net Income	-9.16M	-43.46%	59.12%
EPS	-0.01	-43.08%	59.39%

Key Financial Ratios

Gross Profit Margin

Excellent

65.70%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Weak

-1.66%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-1.46%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.04%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.04%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

11.50

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.01

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-3.74x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.59x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2026	8.10	-0.01	+15.7%	View
Q2 2026	6.96	-0.01	+13.6%	View
Q1 2026	6.50	-0.07	+3.8%	View
Q4 2025	7.90	-0.01	+7.6%	View
Q3 2025	7.00	-0.01	+10.2%	View
Q1 2025	6.26	-0.01	+14.2%	View

ZOM

Zomedica Corp

Q3 2026 Report

Zomedica Corp (ZOM) QQ3 2026 Earnings Review: Revenue Growth Amid Ongoing Losses and a Robust Balance Sheet in Veterinary Diagnostics...

Read full report

ZOM

Zomedica Corp

Q2 2026 Report

Zomedica Corp (ZOM) QQ2 2026 Earnings Review – Revenue Growth, Solid Gross Margin, and Ongoing Losses Amid Strategic Investments...

Read full report

ZOM

Zomedica Corp

Q1 2026 Report

Zomedica Corp (ZOM) Q1 2026 Financial Results Report: Addressing Financial Headwinds Amidst Growth Challenges...

Read full report

ZOM

Zomedica Corp

Q4 2025 Report

Zomedica Corp (ZOM) Financial Results Q4 2025: A Challenging Quarter Highlighting Opportunities in Veterinary Diagnostics...

Read full report

ZOM

Zomedica Corp

Q3 2025 Report

Zomedica Corp (ZOM) Q3 2025 Earnings Report: Continued Growth in Revenue Amidst Operational Adjustments and Market Dynamics...

Read full report

Zomedica Corp (ZOM) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More ZOM Quarterly Reports

ZOM

ZOM

ZOM

ZOM

ZOM

Q1 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

ZOM Full Profile

ZOM Financial Statements

Earnings Calendar